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Abstract
Mutation of the staphylococcal accessory regulator (sarA) limits biofilm formation in diverse strains of Staphylococcus aureus,
but there are exceptions. One of these is the commonly studied strain Newman. This strain has two defects of potential
relevance, the first being mutations that preclude anchoring of the fibronectin-binding proteins FnbA and FnbB to the cell
wall, and the second being a point mutation in saeS that results in constitutive activation of the saePQRS regulatory system.
We repaired these defects to determine whether either plays a role in biofilm formation and, if so, whether this could
account for the reduced impact of sarA in Newman. Restoration of surface-anchored FnbA enhanced biofilm formation, but
mutation of sarA in this fnbA-positive strain increased rather than decreased biofilm formation. Mutation of sarA in an saeS-
repaired derivative of Newman (P18L) or a Newman saeRS mutant (DsaeRS) resulted in a biofilm-deficient phenotype like
that observed in clinical isolates, even in the absence of surface-anchored FnbA. These phenotypes were correlated with
increased production of extracellular proteases and decreased accumulation of FnbA and/or Spa in the P18L and DsaeRS
sarA mutants by comparison to the Newman sarA mutant. The reduced accumulation of Spa was reversed by mutation of
the gene encoding aureolysin, while the reduced accumulation of FnbA was reversed by mutation of the sspABC operon.
These results demonstrate that saeRS and sarA act synergistically to repress the production of extracellular proteases that
would otherwise limit accumulation of critical proteins that contribute to biofilm formation, with constitutive activation of
saeRS limiting protease production, even in a sarA mutant, to a degree that can be correlated with increased enhanced
capacity to form a biofilm. Although it remains unclear whether these effects are mediated directly or indirectly, studies
done with an sspA::lux reporter suggest they are mediated at a transcriptional level.
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Introduction
Staphylococcus aureus is capable of causing diverse forms of human
infection. Understanding the pathogenesis of these infections is
complicated by the diversity among clinical isolates of S. aureus,
and this makes it imperative to understand the impact of this
diversity on clinically relevant phenotypes. Two of the most
important of these phenotypes are toxin production and biofilm
formation, with the former being a defining characteristic of acute
infections and the latter being a defining characteristic of chronic
infections [1]. We have a specific interest in chronic orthopaedic
infections, and in this context we have placed a primary emphasis
on biofilm formation as a contributing factor to the therapeutic
recalcitrance of these infections to conventional antimicrobial
therapy [2]. The therapeutic outcome in such infections is often
poor irrespective of the antibiotic resistance status of the offending
strain [3].
We demonstrated that mutation of the staphylococcal accessory
regulator (sarA) limits biofilm formation in genotypically and
phenotypically diverse clinical isolates of S. aureus to a degree that
can be correlated with increased antibiotic susceptibility under
both in vitro and in vivo conditions [4,5]. This suggests that
inhibitors of sarA expression and/or function could be used to
therapeutic advantage. However, the efficacy of such inhibitors
could be compromised by two experimental observations made
during the course of these studies. The first is that in some strains
mutation of sarA has also been associated with increased
production of alpha toxin [6], an important virulence factor in
many forms of S. aureus infection, including those caused by isolates
of the USA300 clonal lineage [7]. To address this issue, we
explored the mechanistic basis for the strain-dependent impact of
sarA on toxin production, and the results led us to conclude that,
with few exceptions, mutation of sarA results in reduced
accumulation of critical extracellular toxins, including alpha toxin
and phenol soluble modulins (PSMs), at least as assessed under in
vitro conditions [8]. One of the exceptions is the commonly studied
strain Newman, which is characterized by a point mutation that
results in constitutive activation of the saePQRS regulatory system
[9], and we confirmed that this accounts for the apparent increase
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mutant, owing to the limiting impact of saeRQRS on the
production of extracellular proteases [8].
The second potentially compromising factor is that the impact
of mutating sarA on biofilm formation is also strain-dependent,
with Newman once again being a primary example. This is
potentially relevant in that we have also demonstrated that the
increased production of extracellular proteases plays an important
role in defining the biofilm-deficient phenotype of S. aureus sarA
mutants [10,11]. Based on these observations, it would be
anticipated that Newman would have an enhanced capacity to
form a biofilm owing to its reduced production of extracellular
proteases, but we have found that this is not the case [12].
However, the biofilm phenotype of Newman is further compli-
cated in that fnbA and fnbB, which encode fibronectin-binding
proteins (FnbA and FnbB), which are known to contribute to
biofilm formation in S. aureus [13,14], have nonsense mutations
that result in the production of truncated proteins that cannot be
anchored to the cell surface [15].
These two defects are interrelated in that, like sarA, saeRS
enhances transcription of fnbA as well as other surface-associated
binding proteins [16]. Thus, one possible explanation for the
biofilm-deficient phenotype of sarA mutants is the reduced
production of surface-associated proteins such as FnbA. However,
several reports have suggested that the reduced capacity of S. aureus
sarA mutants to bind fibronectin is defined by the increased
production of extracellular proteases rather than transcriptional
changes in expression of the fnbA or fnbB genes [6,17]. Thus, both
saeRS and sarA impact the production of adhesins known to
contribute to biofilm formation [16] and proteases known to limit
the accumulation of these adhesins. The fact that Newman is
lacking surface-anchored FnbA therefore raises the possibility that
the reduced capacity of Newman to form a biofilm, and the
reduced impact of sarA on biofilm formation, are both due to the
reduced availability of a critical surface-associated target of
extracellular proteases.
To investigate this, we restored the ability of Newman to
produce surface-associated FnbA and examined the impact on
biofilm as a function of sarA. While this did enhance biofilm
formation, it also reversed the biofilm-deficient phenotype of the
isogenic sarA mutant, with the fnbA-positive Newman sarA mutant
exhibiting an enhanced capacity to form a biofilm. Subsequent
studies demonstrated that this is due to constitutive activation
saeRS, resulting in reduced production of extracellular proteases
and consequently increased accumulation of both FnbA and
protein A (Spa).
Results
As in our previous studies [12], Newman was found to have a
reduced capacity to form a biofilm by comparison to the clinical
isolate UAMS-1, and mutation of sarA resulted in only a modest
decrease in biofilm formation (Fig. 1). Introduction of an intact
copy of fnbA on a plasmid (pFnbA) increased biofilm formation in
Newman to levels that approached those observed with UAMS-1,
suggesting that the inability to anchor FnbA to the cell surface
contributes to the reduced capacity of Newman to form a biofilm.
This effect was also apparent in a derivative of Newman in which
the saeS defect was repaired (P18L), but it was moderated in an
isogenic saeRS mutant, a phenotype that is consistent with the
demonstration that activation of saeRS enhances transcription of
fnbA [16]. More importantly, mutation of sarA in the pFnbA
derivative of Newman resulted in an increased rather than
decreased capacity to form a biofilm (Fig. 1). In contrast, mutation
of sarA in both the P18L pFnbA derivative and the pFnbA saeRS
mutant limited biofilm formation to a degree comparable to that
observed in a UAMS-1 sarA mutant (Fig. 1). However, this was
also true in sarA mutants generated in these strains in the absence
of pFnbA, thus suggesting that the disparate sarA-dependent
biofilm phenotypes observed in Newman vs. its saeRS derivatives
involve something other than the impact of saeRS on the
production of surface-associated FnbA.
Newman encodes both fnbA and fnbB, with the defect in these
genes precluding anchoring of the corresponding proteins to the
cell surface but not their production [15]. This raises the possibility
that the increased production of extracellular forms of these
proteins impact the sarA-dependent biofilm phenotype. This is
particularly true since protein A has been shown to promote
biofilm formation in both its surface associated and extracellular
forms [18]. To investigate this, we generated fnbA/fnbB mutants in
Newman, its sarA mutant, and their pFnbA derivatives and
assessed the impact on biofilm formation, but this had little impact
on biofilm phenotype of the Newman pFnbA sarA mutant (Fig. 2).
This provides further support for the hypothesis that these
disparate phenotypes are due to something other than the impact
of saeRS on the transcription of fnbA.
When we examined the production of extracellular proteases in
Newman and its saeRS and sarA derivatives, we found a direct
correlation between the production of these proteases and the
functional status of both saeRS and sarA. Specifically, protease
production was lowest in Newman and increased progressively as
the relative activity of both saeRS and sarA declined (Fig. 3). Most
importantly, while mutation of sarA resulted in increased
production of multiple extracellular proteases in all strains, this
effect was moderated in a Newman sarA mutant. This was also
evident in reporter assays using an sspA::luxABCDE reporter,
suggesting that these changes occur at the transcriptional level.
When we examined the accumulation of surface-associated
FnbA, we found that it was present in reduced amounts in the
pFnbA Newman sarA mutant by comparison to pFnbA Newman,
and that this effect was reversed by mutation of sspABC (Fig. 4). In
contrast, mutation of the gene encoding aureolysin (aur) had little
impact on the FnbA phenotype of the Newman sarA mutant.
Surface-associated FnbA was also detected in pFnbA P18L, but it
was reduced to almost undetectable levels in the isogenic sarA
mutant, and concomitant mutation of sspABC had relatively little
impact. This was surprising in that production of both SspA and
SspB was higher in a P18L sarA mutant than a Newman sarA
mutant (Fig. 3), thus suggesting that mutation of sspABC would
have a greater impact on the accumulation of FnbA in the P18L
sarA mutant. Nevertheless, these same relative levels of FnbA
production were evident in the context of biofilm formation, with
mutation of sspABC enhancing biofilm formation in a pFnbA
Newman sarA mutant, albeit to a modest extent, but having no
impact on biofilm formation in the pFnbA P18L sarA mutant
(Fig. 4). This suggests that, while surface associated FnbA is
important, some other difference(s) must also exist between these
strains that is (are) both relevant to biofilm formation and
moderated in an saeRS-dependent manner.
Mutation of aur enhanced biofilm formation in a P18L sarA
mutant, but had no impact on biofilm formation in a Newman
sarA mutant, and this was true irrespective of the presence of
pFnbA (Fig. 5). However, the lack of a phenotype in the pFnbA
Newman sarA/aur mutant must be taken in context in that biofilm
formation was already elevated in the isogenic pFnbA Newman
sarA mutant, meaning biofilm formation in this strain may be at a
maximum defined by this assay. However, the observation that
these same disparate sarA/aur phenotypes were apparent in the
Impact of saeRS and sarA on S. aureus Biofilms
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dependent biofilm phenotype in S. aureus that cannot be explained
by the impact of proteases on the accumulation of surface
associated FnbA.
Mutation of saeRS or sarA has also been associated with reduced
production of Spa, and this has been attributed to transcriptional
changes [19]. However, like FnbA, the production of extracellular
proteases has been shown to limit the accumulation of Spa [17].
The production of Spa in both its surface-associated and
extracellular forms (eSpa) has also been correlated with an
enhanced capacity to form a biofilm [18]. Based on these
considerations, we examined the relative levels of surface-
associated and eSpa in Newman and all of its saeRS and sarA
derivatives. The amounts of both were comparable in Newman, its
P18L derivative, and its isogenic saeRS mutant (Fig. 6). While
indirect, this suggests that saeRS has relatively little impact on spa
transcription. In contrast, the amount of both surface-associated
and eSpa was decreased in a Newman sarA mutant, but decreased
even further in the isogenic P18L sarA and saeRS/sarA mutants
(Fig. 6), corresponding with biofilm formation (Fig. 1). The fact
that this was protease mediated was confirmed by demonstrating
that concomitant mutation of aur reversed this phenotype (Fig. 6).
Thus, one explanation for the increase in biofilm formation in a
pFnbA Newman sarA mutant is the relatively high availability of
FnbA and Spa by comparison to P18L sarA and saeRS/sarA
mutants, resulting in an enhanced capacity to form a biofilm in the
former and a biofilm-deficient phenotype in the latter. In a pFnbA
Newman sarA mutant, this would be presumably be due to both
increased transcription of fnbA [16] and decreased degradation of
the resulting protein. If this is true, then it would be anticipated
that, in the absence of pFnbA, mutation of spa in a Newman sarA
mutant would limit biofilm formation to a degree comparable to
that observed in a P18L sarA mutant, and we found that this was in
fact the case (Fig. 7).
Figure 1. Impact of saeRS and surface-associated FnbA on biofilm formation in Newman. Surface-anchored FnbA was restored in Newman
(New), its saeS-repaired derivative (P18L), and its isogenic saeRS mutant (sae) by introduction of a plasmid-borne copy of fnbA. Biofilm formation was
assessed using a microtiter plate assay, with UAMS-1 (U1) and its sarA mutant included as positive and negative controls, respectively. sarA mutants
are designated as ‘‘S.’’ Asterisks indicate statistical significance (p,0.05) by comparison to the isogenic parent strain (WT).
doi:10.1371/journal.pone.0038453.g001
Figure 2. Impact of endogenous fibronectin-binding proteins on biofilm formation in Newman. Biofilm formation was assessed using a
microtiter plate assay in Newman with and without introduction of surface-anchored FnbA (pFnbA) and/or mutation of its endogenous fnbA and
fnbB. Asterisks indicate statistical significance (p,0.05) by comparison to the isogenic parent strain (WT).
doi:10.1371/journal.pone.0038453.g002
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by examining the impact of mutating one on the other. The
relative activity of saeRS had no impact on the production of SarA,
but mutation of sarA resulted in reduced transcription of saeRS
even in the context of the otherwise constitutive activation of saeRS
in Newman (Fig. 8). However, even with decreased, but not
elimination of, saeR transcription, constitutive activation of the
saePQRS operon can be achieved by constitutive phosphorylation
of SaeR by SaeS. This transcriptional downregulation of saeR by
SarA was true in the USA300 isolate FPR3757 as well. Moreover,
mutation of saeRS in FPR3757 was correlated with a reduced
capacity to form a biofilm (Fig. 9). Importantly, while this biofilm-
deficient phenotype was not apparent in a comparison of pFnbA
Newman and its pFnbA saeRS mutant, it was apparent in a
comparison of pFnbA P18L and the pFnbA saeRS mutant, in
which the functional status of saeRS and fnbA are similar to
Figure 3. Impact of saeRS and sarA on protease production. Production of extracellular proteases in derivatives of Newman as a function of
saeRS and sarA was assessed by zymography using gelatin as the substrate. The presumed identity of individual proteases is indicated to the right.
The graph illustrates relative expression levels the sspA promoter as assessed using an sspA::lux reporter. Differences between the Newman sarA
mutant, the P18L sarA mutant, and the saeRS/sarA mutant were all statistically significant (p,0.05) by comparison to Newman. Differences between
the sarA/saeRS and the P18L sarA mutants, and between the P18L sarA mutant and the Newman sarA mutant, were also significant.
doi:10.1371/journal.pone.0038453.g003
Figure 4. Impact of sarA, saeRS, and extracellular proteases on accumulation of FnbA and biofilm formation. Top: Relative amounts of
surface-anchored FnbA were assessed in Newman (New), its saeS-repaired derivative (P18L), and its saeRS mutant (sae) after introduction of an intact
copy of fnbA on a plasmid. Newman without this plasmid was included as a negative control. The impact of mutating sarA was assessed in each of
these strains together with the impact of mutating the gene encoding aureolysin (aur), sspABC (ssp)o rsae on the phenotype of the sarA mutants.
Bottom: Biofilm formation was assessed by microtiter plate assay in Newman and P18L as well as their sarA and sarA/ssp derivatives after the
introduction of pFnbA.
doi:10.1371/journal.pone.0038453.g004
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defect in the FPR3757 saeRS mutant was modest, particularly by
comparison to mutation of sarA, it was nevertheless statistically
significant, and this phenotype could be ‘‘complemented’’ by
mutation the genes encoding specific extracellular proteases
(Fig. 9). This, along with the observation that mutation of saeRS
has no effect on biofilm formation in a FPR3757 sarA mutant,
suggests that mutation of saeRS resulting in inactivation would not
jeopardize therapy with a sarA inhibitor. Furthermore, these results
further demonstrate the correlation between reduced saeRS
expression, increased protease production, and a reduced capacity
to form a biofilm, and these correlations are independent of, but
synergistic with, the impact of sarA on these same phenotypes.
Discussion
The saePQRS regulatory system has been implicated in biofilm
formation in both S. epidermidis and S. aureus [20,21]. In
S. epidermidis, mutation of saeRS enhances biofilm formation, and
this has been correlated with increased autolysis and the increased
availability of extracellular DNA [21]. In contrast, the only study
examining the impact of saeRS on biofilm formation in S. aureus,
which was also done with Newman, found that mutation of saeRS
resulted in a reduced capacity to form a biofilm [20]. In fact,
mutation of saeRS limited biofilm formation in this study to a
degree that exceeded even that observed with the isogenic sarA
mutant [20]. This was attributed to reduced transcription of the ica
operon and the genes encoding the secreted proteins Emp and Eap
[20].
We were unable to reproduce this phenotype using our assay
conditions. Specifically, Newman, its P18L derivative, and its
isogenic saeRS mutant exhibited a comparable capacity to form a
biofilm that significantly exceeded that observed with the isogenic
Newman sarA mutant. However, there are two potentially
important experimental differences that could explain this
discrepancy. First, the earlier study focused on biofilm formation
under iron-limited conditions [20], which we did not address in
our experiments. The second and potentially more important,
Figure 5. Impact of aureolysin on saeRS and sarA-dependent biofilm formation. Biofilm formation was assessed in Newman, its P18L
derivative, and their sarA, sarA/aur and sarA/ssp mutants with (left) and without (right) the introduction of an intact copy of fnbA. A single asterisk
indicates statistical significance (p,0.05) by comparison to the isogenic parent strain, while the double asterisk indicates statistical significance
(p,0.05) by comparison to the isogenic sarA mutant.
doi:10.1371/journal.pone.0038453.g005
Figure 6. Impact of saeRS and sarA on the abundance of protein A (Spa). The abundance of surface associated (top) and extracellular Spa
(bottom) was assessed by western blot using anti-Spa antibody. Strains include Newman (WT), its saeS-repaired derivative (P18L), its isogenic saeRS
mutant, and derivatives of each in which sarA was mutated alone or in combination with aur.
doi:10.1371/journal.pone.0038453.g006
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vitro biofilm assays employed a substrate coated with human
plasma proteins. We do this for three reasons, the first being that
implanted medical devices are rapidly coated with plasma
proteins. The second is that coating the substrate with human
plasma significantly enhances biofilm formation in genotypically
and phenotypically diverse strains of S. aureus [12]. The third is
that, with the exception of extracellular nucleases [22], the results
we have observed in all of our in vitro biofilm assays have been
consistent with those we have observed under in vivo conditions.
Most importantly, this is true in the context of sarA, which we have
demonstrated results in a reduced capacity to form a biofilm to a
degree that can be correlated with increased antibiotic suscepti-
bility under both in vitro and in vivo conditions [4,5].
This accounts for our overall focus on limiting the regulatory
functions of sarA as a means of limiting biofilm formation and
thereby enhancing the therapeutic response in the context of S.
aureus biofilm-associated infection. It also accounts for our focus on
Newman in these studies in that mutation of sarA has a limited
impact on biofilm formation in this strain by comparison to
contemporary clinical isolates of S. aureus. The results we present
demonstrate that saeRS and sarA work in concert with each other to
limit the production of extracellular proteases and promote biofilm
formation in S. aureus. Our studies employing an sspA::lux reporter
suggest that this occurs at the transcriptional level, although it
remains unknown whether this effect on proteases occurs via a
direct or indirect mechanism. The production of SarA was
unaffected by the functional status of saeRS, while expression of
saeRS was reduced in a sarA mutant. This was previously reported
to be the case in a COL sarA mutant [23], although it was not
found to be the case in the clinical isolate UAMS-1 [24]. This
suggests that this effect is strain-dependent. Nevertheless, based on
this, we propose a model in which sarA represses the production of
extracellular proteases via both saeRS dependent and saeRS
independent pathways (Fig. 10). At the same time, activation of
saeRS promotes transcription of fnbA. When taken together, this
promotes the accumulation of critical proteins that promote
biofilm formation, including FnbA and Spa. While the saeRS-
independent pathway of sarA-mediated regulation has the greater
overall effect, the saeRS-dependent pathway plays a significant role
in that constitutive activation of saeRS can compromise the impact
of sarA on protease production and biofilm formation. Both sarA
and saeRS also modulate the production of surface adhesins at the
transcriptional level, but in the absence of the reduced production
of extracellular proteases owing to constitutive activation of saeRS,
the phenotypic impact of this is overridden by the degradation of
these adhesins due to the increased production of specific
extracellular proteases, including aureolysin, SspA and/or SspB.
The accessory gene regulator (agr) also influences all of these
phenotypes, but the impact of agr is opposite to that of both sarA
and saeRS (Fig. 10). Additionally, expression of sarA influences the
expression of agr, but mutation of sarA and agr have opposite effects
on protease production, the accumulation of surface-associated
adhesins, and biofilm formation [10]. This demonstrates that it is
also the agr-independent effects of sarA that play the phenotypi-
cally-defining role in biofilm formation [10]. Thus, while mutation
of agr is a common occurrence, particularly under in vivo conditions
[25], this would not have a therapeutically relevant impact on the
use of inhibitors aimed at limiting the expression and/or function
of sarA as a means of limiting biofilm formation. In contrast, since
sarA and saeRS play similar roles in biofilm formation, mutation of
saeRS resulting in inactivation would only augment the therapeutic
effect of such inhibitors.
Figure 7. Impact of protein A on biofilm formation in Newman. Biofilm formation was assessed using a microtiter plate assay in Newman and
its sarA and spa derivatives without the introduction of surface-anchored FnbA. Single asterisks indicate statistical significance (p,0.05) by
comparison to the isogenic parent strain. Double asterisk indicates significance by comparison to the isogenic sarA mutant.
doi:10.1371/journal.pone.0038453.g007
Figure 8. Interactions between sarA and saeRS. Top: Production of
SarA was assessed by western blot using SarA antibody in the indicated
strains (WT) and their isogenic sarA mtuants (S). Bottom: Impact of sarA
on transcription of saeR in post-exponential cultures (OD560=3.0) was
assessed by qRT-PCR. Results are shown relative to those observed with
FPR3757, which were set to a value of 1.0. Asterisks indicate statistical
significance (p,0.05) by comparison to the parent strain.
doi:10.1371/journal.pone.0038453.g008
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enhance the regulatory impact of saeRS to a degree that like
observed in Newman could compromise the therapeutic utility of
therapeutic strategies targeting sarA. This is particularly true since
mutation of sarA in the fnbA-positive derivative of Newman
resulted in an increased rather than decreased capacity to form a
biofilm, at least when assessed using a plasmid-borne copy of fnbA.
Nevertheless, constitutive activation of saeRS as observed in
Newman is associated with a single point mutation [9], and this
makes it imperative to determine whether the limited impact of
mutating sarA on biofilm formation in Newman is therapeutically
relevant in the context of biofilm-associated infection and, if so, to
assess the frequency with which such activating mutations occur
under in vivo conditions with the selective pressure of antibiotic
therapy.
Materials and Methods
Bacterial Strains and Growth Conditions
The S. aureus strains examined in this study are listed in Table 1.
Newman, its saeS-repaired P18L derivative, and its saeRS mutant
were generated as previously described [8]. Experiments done
with the USA300 isolate FPR3757 were done using a derivative in
which the plasmid conferring resistance to erythromycin and
kanamycin/neomycin was cured as previously described [8].
Mutation of sarA, aur, fnbA, fnbB, spa, and sspABC in these strains
was done by W11-mediated transduction from existing mutants
[10,26–29]. The FPR3757 saeRS mutant was constructed using the
pKOR1 system as previously described [30]. All strains were
maintained as stock cultures at 280uC in tryptic soy broth (TSB)
containing 25% (vol/vol) glycerol. For each experiment, the
appropriate strains were retrieved from cold storage by plating on
tryptic soy agar (TSA) with antibiotic selection. Antibiotics were
used at the following concentrations: erythromycin (Erm; 5 mg per
ml), tetracycline (Tet; 3 mg per ml), kanamycin (Kan; 50 mg per
ml), and neomycin (Neo; 50 mg per ml).
For phenotypic assays, strains were grown in TSB supplemented
with 0.5% glucose and 3.0% sodium chloride without antibiotic
selection at 37uC. Biofilm formation was assessed using a static
microtiter plate assay in which the substrate was first coated with
plasma proteins as previously described [12]. For other assays,
cultures were grown with constant aeration and a medium-to-flask
volume ratio of 0.40. The post-exponential growth phase was
defined as an optical density at 560 nm (OD560) of 3.0, while
stationary-phase samples were defined by overnight (16-h) growth.
Plasmid Construction
pLL99 was constructed by amplifying the region containing
attP1 and attP2 from pKOR1 and cloning into pLI50 using KpnI
and XbaI. To construct pFNBA, fnbA and its promoter region
were amplified from UAMS-1 using primers that incorporated the
corresponding att sites and cloned into pLL99 using the Gateway
BP Clonase II enzyme (Invitrogen, Grand Island, NY). The
Figure 9. Impact of saeRS and sarA on biofilm formation in clinical isolates. Biofilm formation was assessed in USA300 strain FPR3757 and its
isogenic sarA and saeRS (sae) mutants. A single asterisk indicates statistical significance (p,0.05) by comparison to the isogenic parent strain.
Differences between the FPR3757 saeRS mutant and the saeRS/aur and saeRS/ssp mutants were not significant.
doi:10.1371/journal.pone.0038453.g009
Figure 10. Model for the synergistic impact of saeRS and sarA
on biofilm formation. Both sarA and saeRS repress the production of
extracellular proteases, with sarA having the greater effect owing to
both direct repression and activation of saeRS transcription. This
repression relieves the protease-mediated ‘‘repression’’ of specific
surface proteins arising from degradation. This in turn promotes
accumulation of these proteins and an enhanced capacity to form a
biofilm. The accessory gene regulator (agr) has the opposite effects on
all of these phenotypes, but, as previously described, the impact of sarA
occurs independently of agr, and sarA is epistatic to agr in this context
(Beenken et al., 2010).
doi:10.1371/journal.pone.0038453.g010
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of the sspABC operon from UAMS-1 and cloning into the EcoR1
site of pMK4 lux ABCDE [31]. All primers used in PCR
amplifications are listed in Table 2.
Western Blotting
Relative amounts of protein A (Spa) were assessed by Western
blot. Primary antibody was rabbit anti-Protein A (Sigma Chemical
Co., St. Louis, MO) used at a 1:4000 dilution. Secondary antibody
was horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (Sigma Chemical Co., St. Louis, MO). Western blots were
developed using SuperSignal West Femto Chemiluminescent
Substrate kit (Thermo Fisher Scientific, Rockford, IL). Extracel-
lular protein A (eSpa) was assessed using standardized cell-free
supernatants. Relative amounts of surface-anchored protein A
were assessed using cell wall extracts prepared as previously
described [32]. Briefly, cells from 1 ml of an overnight culture
standardized to an OD560 of 14 were harvested by centrifugation
at 8,0006g for 3 minutes, washed twice, and resuspended in a
buffer consisting of 40 mM Tris-HCl (pH 7.5), 100 mM NaCl,
20 mM MgCl2,1 6protease inhibitor cocktail (Roche), 27%
sucrose, 100 mg/ml lysostaphin, and 1 unit of DNase (Sigma
Chemical Co., St. Louis, MO). Samples were incubated for 4
hours at 37uC before centrifuging at 60006g for 20 min at 4uC.
Samples for analysis were then collected by TCA precipitation as
previously described [32].
Relative amounts of FnbA were assessed by ligand binding
western blot using whole cell lysates as previously described [33].
Briefly, cells were harvested from stationary phase cultures,
washed twice with water, and lysed by incubation for 20 min at
37uC in phosphate-buffered saline (PBS) containing 1 mM CaCl2,
0.5 mM MgCl2,7 0mg/ml of lysostaphin, and 2 units of DNase
(Sigma Chemical Co., St. Louis, MO). Protein concentrations
were determined by Bradford assay, and 6 mg of protein per
sample loaded on a 3–8% Tris-Acetate SDS-PAGE gel (Invitro-
gen, Grand Island, NY) as previously described [34]. Proteins were
transferred to PVDF membranes and blocked with 1% bovine
serum albumin overnight before being incubated for 2 hours at
room temperature in buffer containing with 15 mg/ml of human
fibronectin (Millipore, Billerica, MA). After washing, membranes
were exposed to murine IgG antibody against the N-terminus of
human fibronectin (Millipore, Billerica, MA) diluted 1:4000. Blots
were then exposed to secondary antibody (horseradish peroxidase
(HRP)-conjugated goat anti-mouse IgG) before development with
the SuperSignal West Femto Chemiluminescent Substrate kit
(Thermo Fisher Scientific, Rockford, IL). Production of SarA was
also assessed using whole cell lysates as previously described [34].
Transcriptional Analysis
To assess the levels of saeRS expression, total bacterial RNA was
isolated using the Qiagen RNeasy mini-kit as previously described
[6]. Quantitative, real-time reverse transcription-PCR (qRT-PCR)
was then performed using saeR-specific primers and a correspond-
ing TaqMan probe (Table 2). Results were calibrated by
Table 1. Bacterial Strains Used in This Study.
Strain Description Reference
UAMS-1 MSSA, osteomyelitis isolate [35]
UAMS-929 UAMS-1, sarA::kan [6]
UAMS-2168 UAMS-1, DsaeRS This Study
UAMS-2171 UAMS-1, DsaeRS, sarA::kan This Study
UAMS-1782 USA300, FPR3757 [10]
UAMS-1804 UAMS-1782, sarA::kan [10]
UAMS-1901 UAMS-1782, sarA::kan, pSARA [10]
UAMS-1794 UAMS-1782, Erm-sensitive [8]
UAMS-1802 UAMS-1794, sarA::kan [8]
UAMS-2258 UAMS-1794, DsaeRS This Study
UAMS-2285 UAMS-1794, DsaeRS, sarA::kan This Study
UAMS-3057 UAMS-1794, DsaeRS, aur::erm This Study
UAMS-3058 UAMS-1794, DsaeRS, sspABC::erm This Study
UAMS-200 Newman [6]
UAMS-2167 Newman, saeS (P18L) (CYL11481) [30]
UAMS-2166 Newman, DsaeRS (CYL11771) [30]
UAMS-988 Newman, sarA::kan [6]
UAMS-2170 Newman, saeS(P18L), sarA::kan [8]
UAMS-2169 Newman, DsaeRS, sarA::kan [8]
UAMS-2250 Newman, sarA::kan, aur::erm This Study
UAMS-2226 Newman, saeS(P18L), sarA::kan, aur::erm [8]
UAMS-190 Newman, fnbA::tet, fnbB::erm (DU5886) [27]
UAMS-3060 Newman, fnbA::tet, fnbB::erm, sarA::kan This Study
UAMS-3047 Newman, sspA::lux This Study
UAMS-3045 Newman, saeS(P18L), sspA::lux This Study
UAMS-3049 Newman, DsaeRS, sspA::lux This Study
UAMS-3048 Newman, sarA::kan, sspA::lux This Study
UAMS-3046 Newman, saeS(P18L), sarA::kan, sspA::lux This Study
UAMS-3050 Newman, DsaeRS, sarA::kan, sspA::lux This Study
UAMS-187 Newman, spa::tet [28]
UAMS-3090 Newman, spa::tet, sarA::kan This Study
UAMS-3091 Newman, saeS(P18L), spa::tet This Study
UAMS-3092 Newman, saeS(P18L), spa::tet, sarA::kan This Study
UAMS-2227 Newman, pFNBA This Study
UAMS-2228 Newman, saeS(P18L), pFNBA This Study
UAMS-3042 Newman, DsaeRS, pFNBA This Study
UAMS-3030 Newman, sarA::kan, pFNBA This Study
UAMS-3031 Newman, saeS(P18L), sarA::kan, pFNBA This Study
UAMS-3043 Newman, DsaeRS, sarA::kan, pFNBA This Study
UAMS-3051 Newman, sarA::kan, aur::erm, pFNBA This Study
UAMS-3080 Newman, sarA::kan, sspABC::erm, pFNBA This Study
UAMS-3052 Newman, saeS(P18L), sarA::kan, aur::erm, pFNBA This Study
UAMS-3081 Newman, saeS(P18L), sarA::kan, sspABC::erm,
pFNBA
This Study
UAMS-3067 Newman, fnbA::tet, fnbB::erm, pFNBA This Study
UAMS-3068 Newman, fnbA::tet, fnbB::erm, sarA::kan, pFNBA This Study
Plasmid
Psara [34]
pLL99 This Study
Table 1. Cont.
Strain Description Reference
pFnbA This Study
sspA::lux This Study
doi:10.1371/journal.pone.0038453.t001
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using primers and a TaqMan probe corresponding to a 16S rRNA
gene (Table 2). Results are reported as relative units by
comparison to the results observed in the indicated strains, with
the latter being set to a value of 1.0.
Production of Extracellular Proteases
Protease activity was assessed by zymogram as previously
described [10] using 10% gelatin gels (Invitrogen, Carlsbad, CA).
Assessment of ssp Expression
Stationary phase (16 hour) cultures were used to inoculate 96-
well white, clear-bottom plates (Corning, Lowell, MA) to an
OD560 of 0.05. Plates were incubated at 37uC for 4.5 hours,
followed by assessment of luminescence on a plate reader.
Statistical Analysis
Statistical analysis of results comparing wild-type strains was
done using the Students t-test. Statistical analysis of results
comparing different strains with their isogenic sarA mutants was
done by ANOVA based on all pair wise comparisons. In both
cases p values ,0.05 were considered significant.
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